1 / 15

PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET ANALYSIS

Read here market analysis report on PLASMA PROTEASE C1-INHIBITOR TREATMEN

yuvhaan
Télécharger la présentation

PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET ANALYSIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/

  2. PLASMA PROTEASE C1-INHIBITOR TREATMENT MARKET ANALYSIS C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.

  3. Market Dynamics Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in

  4. adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.

  5. Key features of the study: • This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers,

  6. restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans • Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

  7. Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics • The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.

  8. Request free sample copy of plasma protease c1-inhibitor treatment market analysis • Request free PDF copy of plasma protease c1-inhibitor treatment market analysis

  9. Figure 1. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Drug Type, 2020

  10. Figure 2. Global Plasma Protease C1-inhibitor Treatment Market Share (%), by Region, 2020

  11. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  12. CMI Services: • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs • CMI Press Releases

  13. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  14. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related